Détail de la revue
Documents disponibles dans cette revue
trié(s) par (Pertinence décroissant(e), Date de parution décroissant(e), Date de parution décroissant(e), Système de projection du document croissant(e)) Mettre toutes les notices dans le panier Faire une suggestion Ajouter un critère de recherche
Spinal muscular atrophy - insights and challenges in the treatment era
Mercuri E, Pera MC, Scoto M, et al.
Nature reviews. Neurology, 2020
The expanding role of MRI in neuromuscular disorders
Carlier PG, Reyngoudt H
Nature reviews. Neurology, 2020
Cladribine shows promise in patients with difficult-to-treat myasthenia gravis
Wood H
Nature reviews. Neurology, 2019
Alternative gene therapy target identified in spinal muscular atrophy mice
Lempriere S
Nature reviews. Neurology, 2019, 15, 10, p 558
Next-generation sequencing in Charcot-Marie-Tooth disease: opportunities and challenges
Pipis M, Rossor AM, Laura M, et al.
Nature reviews. Neurology, 2019
Therapeutic developments for Duchenne muscular dystrophy.
Verhaart IEC, Aartsma-Rus A
Nature reviews. Neurology, 2019, 15, n7, p 373
Long-term benefits of nusinersen in later-onset spinal muscular atrophy
Fyfe I
Nature reviews. Neurology, 2019
Immunotherapy in myasthenia gravis in the era of biologics
Dalakas MC, Dalakas MC
Nature reviews. Neurology, 2019, 15, 2, p 113
A potential biomarker strategy to monitor treatment response in spinal muscular atrophy
Wood H
Nature reviews. Neurology, 2018, 14, 10, p 570
Motor neuron disease: Positive trial results published for ground-breaking SMA therapies
Ridler C
Nature reviews. Neurology, 2018, 14, 1
Peripheral neuropathies: Antisense therapy for Charcot-Marie-Tooth disease?
Ridler C
Nature reviews. Neurology, 2018, 14, 2, p 64
Congenital myopathies: disorders of excitation-contraction coupling and muscle contraction
Jungbluth H, Treves S, Zorzato F, et al.
Nature reviews. Neurology, 2018, 14, 3, p 151
Advances in therapy for spinal muscular atrophy: promises and challenges
Groen EJN, Talbot K, Gillingwater TH
Nature reviews. Neurology, 2018, 14, 4, p 214
Motor neuron disease: A prospective natural history study of type 1 spinal muscular atrophy
Bertini E, Mercuri E
Nature reviews. Neurology, 2018, 14, 4, p 197
Why dystrophin quantification is key in the eteplirsen saga
Aartsma-Rus A, Aartsma-Rus A, Arechavala-Gomeza V
Nature reviews. Neurology, 2018, 14, 8, p 454
Genome engineering: a new approach to gene therapy for neuromuscular disorders
Nelson CE, Robinson-Hamm JN, Gersbach CA
Nature reviews. Neurology, 2017, 13, 11, p 647
Neuromuscular disease: Tadalafil fails to halt the progression of Duchenne muscular dystrophy
Wood H
Nature reviews. Neurology, 2017, 13, 12
Atypical Charcot-Marie-Tooth disease linked to spingosine 1-phosphate lyase deficiency
Wood H
Nature reviews. Neurology, 2017, 13, 2, p 67
Motor neuron disease: Nusinersen potentially effective in SMA
Adams L
Nature reviews. Neurology, 2017, 13, 2
Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line
Dowling JJ
Nature reviews. Neurology, 2016, 12, 12, p 675
Genome editing shows promise in an in vivo model of Duchenne muscular dystrophy
Wood H
Nature reviews. Neurology, 2016, 12, 2, p 63
Skeletal muscle disorders of glycogenolysis and glycolysis
Godfrey R, Quinlivan R
Nature reviews. Neurology, 2016, 12, 7, p 393
Limb-girdle muscular dystrophies - international collaborations for translational research
Thompson R, Straub V
Nature reviews. Neurology, 2016, Epub, 17 p.
Spinal muscular atrophy-recent therapeutic advances for an old challenge
Faravelli I, Nizzardo M, Comi GP, et al.
Nature reviews. Neurology, 2015, 11, 6, p 351
Improved diagnostic sensitivity can aid the correct choise of treatment for patients with myasthenia gravis
Malkki H
Nature reviews. Neurology, 2015, 11
